Monohydrate solvates of loracarbef
OwnerYatendra Kumar, Neera Tewari +3inventors
InventorsYatendra Kumar, Neera Tewari, Hashim Nizar Poovanathi Meeran, Bishwa Rai, Sailendra Singh
Life of this patent
Estimating the term…
Abstract
This invention relates to monohydrate solvates of loracarbef. The invention also relates to processes for preparing solvates of loracarbef, crystalline monohydrate of loracarbef from said solvates and pharmaceutical compositions that include the crystalline monohydrate of loracarbef.
Claims20
Mono N,N-Dimethylacetamide monohydrate solvate of loracarbef of Formula II-A.
Mono N-Methylpyrrolidone monohydrate solvate of loracarbef of Formula II-B.
A process for the preparation of mono-N, N-dimethylacetamide monohydrate solvate of loracarbef of Formula II-A,
- comprising mixing a compound of Formula III,
- wherein R1 is hydrogen, trihalo (C1-C4 alkyl), C1-C4 alkyl, C1-C4 substituted alkyl, C1-C4 alkoxy, C1-C4 substituted alkoxy, C1-C6 alkylthio, C1-C6 substituted alkylthio, methoxy methyl, carbamoyloxy methyl, acetoxymethyl, C2-C6 alkenyl,
- C2-C6 substituted alkenyl, or halogen such as bromo, chloro, fluoro, and iodo;
- and
- R2 is a carboxy-protecting group,
- with N,N-dimethylacetamide and a base to form a free amine of the compound of formula IV, and
- reacting the compound of Formula IV with an acylating agent of Formula V,
- wherein R3 is an amino protecting group and L is a leaving group.
A process for the preparation of mono N-methylpyrrolidone monohydrate solvate of loracarbef of Formula II-B,
- comprising mixing a compound of Formula III,
- wherein R1 is hydrogen, trihalo (C1-C4 alkyl), C1-C4 alkyl, C1-C4 substituted alkyl, C1-C4 alkoxy, C1-C4 substituted aLkoxy, C1-C6 aLkylthio, C1-C6 substituted alkylthio, methoxy methyl, carbamoyloxy methyl, acetoxymethyl, C2-C6 alkenyl, C2-C6 substituted alkenyl, or halogen such as bromo, chloro, fluoro, and iodo;
- and R2 is a carboxy-protecting group,
- with N-methylpyrrolidone and a base, to form a free amine of the compound of formula IV, and
- reacting the compound of Formula IV with an acylating agent of Formula V,
- wherein R3 is an amino protecting group and L is a leaving group.
A process for the preparation of crystalline monohydrate of loracarbef, the process comprising:
- treating mono N,N-dimethylacetamide monohydrate solvate of loracarbef with an acid, and adjusting the pH with a base to afford the crystalline monohydrate of loracarbef.
A process for the preparation of crystalline monohydrate of loracarbef, the process comprising:
- treating mono N-methylpyrrolidone monohydrate solvate of loracarbef with an acid, and
- adjusting the pH with a base to afford the crystalline monohydrate of loracarbef.
Crystalline monohydrate of loracarbef having a bulk density greater than or equal to 0.6 g/ml.
A pharmaceutical composition comprising:
- a therapeutically effective amount of a crystalline monohydrate of loracarbef having a bulk density greater than or equal to 0.6 g/ml;
- and one or more pharmaceutically acceptable carriers, excipients or diluents.
Dependencies are inferred from the claim text.